Halper Sadeh LLC Investigates Lantheus, Atkore, and Indivior Deals for Shareholder Fairness

M&A · PartnershipRegulation
โดย GlobeNewswire·Read original
Summary · why it matters

Halper Sadeh LLC, an investor rights law firm, is investigating whether the proposed sales of Lantheus Holdings, Atkore, and Indivior Pharmaceuticals are obtaining fair deals for their shareholders. The firm is examining Lantheus Holdings' sale to Curium US Holdings for $102.50 per share in cash plus non-transferable Contingent Value Rights providing up to $12.00 per share in potential additional cash payments, Atkore's sale to Prysmian for $95.00 per share in cash, and Indivior's merger with Supernus Pharmaceuticals in which Indivior shareholders would own approximately 56.5% of the combined company. Halper Sadeh LLC may seek increased consideration, additional disclosures, or other relief on behalf of shareholders, and encourages them to contact the firm to discuss their rights at no cost.

Impact on stocks 5

Biotech & Genomic Medicine · 3 stocks
Indivior PLC Ordinary Shares
INDV
± MixedCapitalrelevance

Investigation into Indivior's merger with Supernus, where shareholders would own 56.5% of combined company; may seek better terms.

Lantheus Holdings Inc
LNTH
± MixedCapitalrelevance

Investigation into Lantheus's sale to Curium for $102.50 per share plus CVRs; may seek increased consideration or disclosures.

Supernus Pharmaceuticals Inc
SUPN
± MixedCapitalrelevance

Indivior's merger with Supernus is under investigation; Supernus is the acquirer, potential impact on deal terms.

Energy Transition & Power Demand · 2 stocks
Atkore International Group Inc
ATKR
± MixedCapitalrelevance

Investigation into whether Atkore's sale to Prysmian at $95.00 per share is fair to shareholders; may seek increased consideration.

Prysmian SpA
0NUX
± MixedCapitalrelevance

Atkore's sale to Prysmian is under investigation; Prysmian is the acquirer, potential impact on deal terms.

Off-coverage companies 1

CuriumPrivate± Mixed
relevance